|
**Overview**: Endometriosis Panel**Introduction**: The Endometriosis Panel is a diagnostic tool designed to screen for endometriosis using serum samples. In India, endometriosis affects ~10-15 percent of reproductive-age women, causing chronic pelvic pain, infertility, dysmenorrhea, and dyspareunia, with diagnostic delay averaging 7-10 years due to nonspecific symptoms and reliance on laparoscopy. High burden from underdiagnosis in rural/low-SES women, limited gynecology access, delayed hormonal therapy or surgery leading to infertility or adhesions. Per gynecology practices aligned with ICMR and FOGSI guidelines, the test employs immunoassay for CA 125 and CA 19-9 over 1-2 days with moderate sensitivity/specificity, valuable as adjunct to clinical/ultrasound evaluation (elevated CA 125 common but nonspecific). This diagnostic falls under gynecological screening and targets women with chronic pelvic pain or infertility, addressing supportive detection to guide laparoscopy or medical management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling earlier suspicion and reducing infertility burden. Its serum-based approach ensures reliable noninvasive screening.**Other Names**: Endometriosis Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Tumor markers as adjunct; in India, used in infertility clinics.**Purpose**: The test screens for 2 parameters including CA 125 to guide endometriosis assessment, support clinical suspicion, inform further evaluation.**Test Parameters**: 1. CA 125, 2. CA 19-9.**Pretest Condition**: No fasting required; patients should report pelvic pain, dysmenorrhea, or infertility.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on menstrual pain, infertility duration, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed endometriosis including infertility, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or endometriosis stage can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated CA 125 suggests endometriosis, necessitating specialist input. Normal does not exclude; further evaluation needed.**Specialist Consultation**: Gynecologists should be consulted for management.**Additional Supporting Tests**: Ultrasound, laparoscopy for confirmation.**Test Limitations**: Markers nonspecific; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Endometriosis Studies India 2023. |
